Opioid Antagonist Drug Class List

Drugs in Drug Class: Opioid Antagonist

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Knoa Pharma	ZURNAI (AUTOINJECTOR)	nalmefene hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	218590-001	Aug 7, 2024		RX	Yes	Yes	11,865,112		Y
Knoa Pharma	ZURNAI (AUTOINJECTOR)	nalmefene hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	218590-001	Aug 7, 2024		RX	Yes	Yes	11,857,547		Y
Knoa Pharma	ZURNAI (AUTOINJECTOR)	nalmefene hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	218590-001	Aug 7, 2024		RX	Yes	Yes
Edenbridge Pharms	ZUBSOLV	buprenorphine hydrochloride; naloxone hydrochloride	TABLET;SUBLINGUAL	204242-006	Oct 4, 2016		RX	Yes	No	8,470,361		Y

Opioid Antagonist Market Dynamics and Patent Landscape: Naloxone, Naltrexone, Nalmefene, and Perioperative Reversal

Last updated: July 1, 2026

Executive summary

Opioid antagonists split into two patent-saturated segments. Naloxone (IM/IN/autoinjector) faces repeated reformulation and device patents layered on top of legacy API expiration, driving a fragmented Orange Book and litigation-heavy landscape. Naltrexone (oral and extended-release) and Nalmefene (oral, limited US history) have fewer products but higher concentration in long-acting depot systems where formulation, microsphere, and manufacturing method patents extend exclusivity and constrain generic entry. Across the class, commercial leverage shifts from patent life to device+formulation lock-in, REMS/clinical training workflows, and payer contracting rather than pure API exclusivity.

---

Which opioid antagonist drugs dominate the US market and why?

US opioid antagonist revenue concentration is driven by: (1) emergency reversal demand (hospital and EMS), (2) outpatient overdose preparedness (community distribution and payer programs), and (3) chronic-opioid use disorder (OUD) and alcohol use disorder (AUD) applications that use opioid antagonism mechanisms.

Key commercial products by active ingredient

Naloxone

• Nasal: Narcan (adapted to multiple presentations), plus newer branded/authorized generics where patents allow.
• Injectable: multi-source intramuscular formulations; autoinjector platforms in some markets.
• Form factors: nasal spray and IM have the broadest institutional uptake.

Naltrexone

• Oral: generic-dominant in many geographies.
• Extended-release depot: branded remains structurally protected via formulation and manufacturing IP for long-acting systems.

Nalmefene

• Narrower market footprint; historically less dominant in routine US reversal.

What the market structure implies for patent strategy

• Reformulation and device patents are the gating items for naloxone’s next-wave competition.
• Microsphere/depot and process patents are the gating items for long-acting naltrexone where generic development requires proof that the product meets release and performance specifications under constrained manufacturing IP.

---

What patents protect naloxone products in the US?

Naloxone’s patent estate is a mix of legacy API (largely expired) and secondary IP that covers:

• nasal spray formulations (drug concentration, excipients, solubility/stability)
• device sub-combinations (metering, spray plume, nozzle mechanics)
• manufacturing processes (sterile filtration/aseptic methods where applicable)
• packaging and administration steps where covered by method claims

Common Orange Book entry patterns for naloxone

• Multiple NDA/ANDA ties: same active ingredient across different dosage forms and delivery devices creates parallel patent listings.
• Concentrated “blocking” patents: a small subset of listed patents often drive Paragraph IV positions and settlement outcomes.

Litigation and exclusivity mechanics most relevant to naloxone

• Paragraph IV challenges typically target formulation and device-related patents listed in the Orange Book.
• Cure and settlement: naloxone tends to produce short, targeted settlements that permit market entry at a defined timepoint or under non-infringing product changes.

---

When does naloxone lose exclusivity in the US, and what timelines matter?

Naloxone’s “exclusivity” is less a single event than a set of overlapping milestones:

• patent expiration dates on Orange Book-listed patents (often later than API expiration)
• potential pediatric exclusivity or other FDA exclusivity extensions (where applicable)
• market entry design around device-formulation differences

Featured snippet answer

Naloxone loses protection when the last Orange Book-listed patent covering the specific dosage form and formulation expires, including device-linked patents that survive longer than the underlying API.

Practical timeline framework used in market-entry planning

1. Determine the exact NDA and dosage form (nasal spray vs injectable vs autoinjector platform).
2. Identify the latest expiration among Orange Book-listed patents for that NDA.
3. Run the FDA 30-month clock for Paragraph IV ANDAs (if a challenge exists).
4. Map expected authorized generic or settlement entry dates if litigation ends in consent judgments or licensing.

---

Which patents cover extended-release naltrexone depot formulations and manufacturing?

Extended-release naltrexone (notably the microsphere/depot class) uses a proprietary formulation and manufacturing approach that is typically protected by:

• polymer/drug ratio claims
• microsphere preparation steps and controls
• release profile targets tied to formulation parameters
• sterilization and aseptic processing where relevant

What usually blocks generics in depot naltrexone

• Method-of-manufacture patent claims can force generic reformulation or process changes that still land within claim scope.
• Release kinetics become a proxy for infringement risk when patent language ties release to formulation attributes.

Comparative risk point

• Depot naltrexone generics carry higher patent-infringement risk per development year than oral naltrexone because the claim scope is typically narrower but more product-specific.

---

What patents protect opioid antagonist nalmefene products?

Nalmefene’s US presence is smaller than naloxone and naltrexone. Patent coverage is more likely to relate to:

• oral formulations (stability and dosing form)
• manufacturing steps
• any late-stage reformulations tied to regulatory updates

Market implication

If branded nalmefene is not widely used at scale, generic entry can happen earlier, and patent enforcement intensity tends to be lower. The practical gate becomes whether any Orange Book-listed secondary patents remain for current product labels.

---

How strong is the patent estate for opioid antagonists overall?

Strength varies by subsegment:

Naloxone: fragmented, enforcement-heavy on specific delivery platforms

• strength often comes from dosage form and device patents rather than novel pharmacology
• the estate is usually “broadly expired, narrowly protected” in active product configurations

Extended-release naltrexone: fewer products, concentrated IP barriers

• strong due to microsphere formulation and manufacturing claims
• generic entry is harder because showing equivalence does not automatically avoid process/formulation infringement

Net assessment for business planning

• Naloxone: entry timing depends on a small set of blocking patents tied to delivery mechanism.
• Naltrexone depot: entry timing depends on whether the generic can design around release-linked formulation and manufacturing claims.

---

What is the Orange Book status of opioid antagonists like Narcan and extended-release naltrexone?

Orange Book status is typically the single fastest way to map real-world exclusivity. For this class, entries usually include:

• listed patents with varying expiration dates
• multiple patents per NDA often clustered around the same late-stage reformulation or manufacturing process

Featured snippet answer

Orange Book protection for opioid antagonists is usually concentrated in secondary patents for specific dosage forms and delivery devices, not in the original API patents.

---

Which companies are challenging opioid antagonist patents via Paragraph IV?

Paragraph IV challenges tend to cluster around:

• naloxone nasal spray reformulation/device patents
• extended-release naltrexone depot formulation and manufacturing patents

Typical challenger profile

• established generic manufacturers with ANDA throughput and litigation capability
• companies that can pivot quickly from one delivery device variant to another to mitigate injunction risk

Practical litigation outcome pattern

• settlements often result in delayed entry, authorized generic schedules, or narrow design-arounds that avoid the highest-risk patents.

---

What patent litigation affects naloxone and naltrexone market entry most?

Patent litigation in this class typically affects market dynamics via:

• injunction threats that force settlement
• design-around changes that require FDA supplements or manufacturing process requalification
• consent judgments that lock in entry at a defined date

Injunction risk drivers

• whether a court finds the challenged claims are infringed and not invalid
• whether the challenged patents are key to commercial product identity (device/formulation)

---

How do settlement agreements typically change launch calendars for opioid antagonist generics?

Settlement agreements in opioid antagonist cases commonly do three things:

1. confirm patent validity for at least one blocking patent
2. set a payoff date (delayed entry date or staged launch)
3. allow limited entry under an authorized generic or design-around conditions

What matters commercially

• the settlement “entry window” often becomes the real exclusivity end date for market access planning
• payer contracting frequently follows the expected entry calendar, making time shifts costly

---

What generic entry risks exist for nasal naloxone versus injectable naloxone?

Risk differs by product:

• Nasal: device and formulation patents are central; design-around requires careful attention to spray mechanics and excipient formulation.
• Injectable: fewer device elements can shift risk toward sterility/method-of-manufacture and concentration/formulation patents.

Business conclusion

Nasal naloxone often shows more “product identity” IP, so generics face higher diligence burden on device mechanics and formulation stability.

---

How does extended-release naltrexone compare with oral naltrexone on IP barriers?

• Oral naltrexone has mostly cleared API-era protection; generic adoption is easier.
• Extended-release naltrexone remains constrained by depot formulation and manufacturing IP.

Key comparison point

Extended-release naltrexone has fewer competition substitutes within the same dosing experience, so brands maintain stronger contracting leverage even when oral competition is robust.

---

Which opioid antagonist formulations are most often patented?

Across the class, formulation patents commonly cover:

• excipient systems influencing stability and delivery performance
• concentration-specific drug loading and pH/solubility windows
• spray formulation parameters for nasal delivery
• microsphere or matrix release-control parameters for depot dosing

Delivery-system cluster map

• Nasal spray: excipients + device metering + plume characteristics
• Depot: microsphere composition + manufacturing process + release profile
• Injectable: sterility assurance + composition + concentration

---

What manufacturing/IP barriers stop generic opioid antagonists?

The recurring barriers:

• process patent scope for depot products, including specific process steps and controls
• aseptic processing requirements that overlap with method claims
• device subcomponent design that must avoid claim scope without triggering clinical performance deviations

---

Revenue exposure: how much of opioid antagonist spend is at risk from patent expiry?

Spend-at-risk is driven by:

• number of formulary placements for each dosage form
• exclusivity end dates by NDA/presentation
• payer preferences for specific delivery formats

Practical revenue exposure logic used by licensing and investment teams

• identify top 3 brands by net sales in naloxone and extended-release naltrexone
• map their Orange Book blocking patents to their expected expiration windows
• overlay known generic challenge and settlement entry dates

---

Key Takeaways

• Naloxone’s IP is mostly secondary and dosage-form/device focused, so market entry is gated by a small set of blocking patents tied to the specific delivery platform.
• Extended-release naltrexone faces concentrated formulation and manufacturing barriers that make generics more schedule-sensitive and settlement-prone.
• “Exclusivity” for opioid antagonists is best treated as a stack of Orange Book patent expirations plus litigation-driven settlement entry dates, not a single API expiration date.
• The biggest commercial differentiators are delivery format fit, payer contracting, and workflow adoption, all of which get reinforced by device and formulation IP.

---

FAQs

1) Which opioid antagonist has the most active patent blocking for US generics, naloxone or naltrexone?

Naloxone generally shows more activity in reformulation/device blocking for specific delivery platforms, while extended-release naltrexone shows higher concentration risk per depot product due to formulation and manufacturing claim scope.

2) Do opioid antagonist device patents matter as much as formulation patents?

For naloxone nasal products, device-linked and administration mechanics patents often matter as much as formulation, because generic success depends on both claim avoidance and delivery performance.

3) What tends to trigger Paragraph IV filings for opioid antagonists?

Listings of secondary Orange Book patents tied to dosage form performance (nasal spray characteristics) and manufacturing/release characteristics (depot systems) are the most common triggers.

4) How do patent settlements for naloxone usually structure generic entry?

They commonly set delayed entry dates, authorize limited market supply under agreed terms, and/or require specific non-infringing product design choices.

5) Are method-of-manufacture patents a primary risk for depot opioid antagonists?

Yes. Depot systems often face the highest method/process infringement risk because claim scope can cover specific formulation and production steps tied to release control.

---

References

1. FDA. “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.” U.S. Food and Drug Administration. (Accessed 2026-07-01). https://www.accessdata.fda.gov/scripts/cder/daf/
2. FDA. “Drugs@FDA.” U.S. Food and Drug Administration. (Accessed 2026-07-01). https://www.accessdata.fda.gov/scripts/cder/daf/